Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, indeed, it says update. However, it also says DC VAX and not DC VAX L. At this point there is little interest in an update on D or combo trials. The focus is upon L period. If there isn't significant update on L, the share price will be in free fall.
I don't expect top line. I don't think that the absence of an abstract precludes announcing it at Industry Theatre. It is possible that LP did not want to give a heads up to the shorts by abstract and possible leaks so she is playing this close to the vest. However, it is unlikely and I have a feeling that the SAPs have not been submitted yet. This is a question that will dog them at Industry Theatre. A stay tuned won't cut it and "all I can tell you is that it is a ginormous task, blah, blah, blah" will only serve to accelerate the dive in share price.
Therefore, I doubt LP is so stupid as to come into Industry Theatre with nothing but her "Crown Jewels" in hand. If nothing of substance is revealed in updating L, then I will have to agree with Scotty on his assessment of her. I am betting that it won't essentially be the same old and having MB as a presenter is positive. I think we get something and it is hard to see how they can avoid updates on SAP progress. Otherwise, we are headed quickly to new lows. JMHO.
I agree with your post. And I believe the odds of top line announcement at ASCO are small. This does not bother me or other reasonable investors.
What may be frustrating is that ASCO 2019 comes and goes without any notable update on DC VAX L. At this point, what investors are interested in are updates and focus upon DC VAX L, not the generic DC VAX as was stated as the topic for Industry Theatre. For now "D" takes a second seat. Combo trials have been scheduled in the past only to be interminably postponed for whatever reason.. A successful "L" will give much more credence and excitement for "D" and other combos. But let's get "L" done first.
Obviously, top line scheduling is not fully within the control of NWBO. A pacing--and important--item is the approval of the SAPs by the requisite RAs. We get all that.
However, I believe that there is some notable information that NWBO can disclose. They can provide status on the SAPs. Have they been completed? Have they been submitted to the RAs? When were they submitted? Have they collected all the data from all sites? Where are they with respect to the resolution of queries, etc, etc. They can easily show a chart with all the tasks required for announcing top line and where they are in the processes and which are being done in parallel. There is other information that they can share. For example, how many patients are still alive? They provided that number in the JTM. Why not an update?
I think that ASCO is a pivotal event. So do other investors who I know. There are expectations for ASCO 2019 and hopefully it will not come and go with nothing to show for it. I believe that the lack of top line announcement will negatively affect the share price. However, its' depreciation can be mitigated to some significant extent by providing new news. At the very least, SAP status. A regurgitated dog and pony show would be a huge disappointment and would be reflected in the un-necessary punishment of the share price. I certainly think that LP, LG and DI realise all this and are not going to Industry Theatre to stand there in a room with no clothes on. It is much easier to get lift-off on the share price from current levels than to have to climb out of a black-hole of new lows in the share price despite positive results. I do think that as part of management's responsibilities, they have an obligation to preserve value where they can. I believe that they are in possession of some meaningful DC VAX L updates that they can share at ASCO. After all, one of the directors at the ASM indicated that we need to get the share price up and that we should be looking for more news within three or four months. Management can do something at ASCO, even short of announcing top-line, to try and preserve that value. JMHO.
Never said "lost the war". But do question whether they are "winning the war". So far it does not look like it. I trust that you invest better than you read.
Happy:
I am betting that this year, ASCO will be different. I am betting that LP is not stupid and realizes the devastation to share price if ASCO comes and goes without any announcement of top line or lacking that, noteworthy news focused upon DCVAX L. Diverting attention to combo trials, etc. won't work. The market is focused upon L. If results are unduly delayed and if less than stellar, the market could care less about D or anything else. LP, and of course DI, realize all this and what will most likely happen to the share price. To let ASCO 2019 come and go without any more than an essentially stay tuned outcome just invites serious share price depreciation. And the longer it goes on, the harder the share price spanking.
If, for example, the share price tanks to $0.15, even with good news, a significant portion of the rise in share price is spent recouping to present levels. If the multiple is 6x, over 2x of it or more than one-third of the multiple energy is wasted upon recoupment to where we are now. What a waste. And from that low level, it is quite likely that the price does not even reach a dollar.
Furthermore, the longer nothing happens in terms of news/announcement, there will be increasing concerns about financing. To avoid dilution, NWBO may be forced to "fire-sale" its remaining tangible asset. In the process, NWBO is left without a "cushion" and will be at the mercy of malevolent market forces and extremely toxic financing alternatives. This concern will weigh more heavily as time marches on and overhang the share price. Hence, it is imperative that LP, LG and DI do something at ASCO to help protect the share price or at least mitigate its fall if there is no top line announcement. There is no doubt that they are in possession of new and updated information. How they choose to present it or not at ASCO will be critical in my view. They can buy a bit of time if they do it right, but certainly not to December, 2019. Even mentioning such a "drop dead" date will only serve to accelerate any downdraft in share price. The market will perceive it as trouble and further delay. And even a drop dead date can be cavalierly changed. In LG's words......sh*t happens, circumstances change, nothing is etched in stone....And, of course, neither LP or LG enjoy much credibility in the market place. Their December drop dead date is just another ploy to distract and delay in order to buy time....and for what asks Wall Street. Having management go on record, so to speak, won't change anything if they go on with their well worn excuses of "things change, we don't have a crystal ball, blah, blah." Then what do you do? To me, it is just kicking the can further down the road.......to perhaps a dead end?
The time is well nigh for at least a very meaningful DC VAX L update and top line announcement sometime during the summer. Instead of suggesting giving them more time, e.g., until December, 2019, shareholders need to keep management's feet to the fire. Management was roundly supported in its request to increase shares. However, over a year later, we have less than 34 cents a share, probable further delay in top line announcement which was expected almost 6 months ago, further possible devastation of the share price and concerns about financing and a fire sale of the last of our remaining tangible assets. And yet, some on this MB still want to give them the benefit of the doubt and would not object to giving them even more slack. IMHO, those holding such views only encourage management to continue with the status quo of silence, obfuscation and delay. They don't know when enough is enough. Contrary to your opinion, I think if ASCO comes and goes with nothing, many investors are going to reassess their positions. There will be serious questions concerning management's competence and stupidity, waste of resources and DI's influence. Hopefully, DI is not just a place holder for LG. What happens at ASCO will certainly shed some light as to the degree of his influence or lack thereof as a shareholder advocate. I doubt there will be significant interest by any new investors. I think it would be a hard sell for DI.
JMHO.
Really? At less than $0.34?
So what? And when do you think this will be decided by the courts? After all the interlocutory appeals and then appeals to Court of Appeals and then the Supreme Court after remand upon remand to try specific fact exceptions, we will all be long gone. Do you think the US can overcome the firepower and resources of big P? Don't be silly. Big P is a master at strategic litigation and they have the best legal minds at hand to obfuscate, delay and confuse.
No top line announcement by ASCO and nothing new of any substance is revealed wrt DC VAX L by then, the share price gets taken to the woodshed. One sentence, how's that?
Woooohpie, so they finally made a deadline by filing the 10K on time. OK, I stand corrected. They failed to make any deadlines, except one recently met. Now this changes everything!
You have entirely misunderstood my posts. Re-read them. I'm not going through the trouble of explaining again. Good luck.
Happy, that is the problem. And that is one of the main reasons the stock is in the dumper. A lot of the loss of market value can be attributed to management's inability to be reasonably transparent. They have lost all credibility.
I disagree with you on the December date. Your point is that if a date certain is set by which top line will be announced, then this will go a long way to placate irate shareholders who are ultimately reasonable people. OK, how about if they set a date certain that by no later than ASCO 2020 top line will be announced. Would you accept that? Would you be somewhat placated? How about March, 2020?
No, Happy, just like the December date you state, these are too far out and the share price gets decimated. Shareholders have been reasonable. Many expected top line nlt end of 2018. Did not happen. Then, nlt than March, 2019. Didn't happen. Certainly by ASCO 2019 and it looks like it won't happen. Even if they say by December, 2019, who would believe them? They have not met even one guideline. What happened to the string of PRs that LG mentioned to me and others by telephone conversation at least twice long, long ago?? What happened to the filing of the lawsuit? It goes on and on. LG's favourite riposte is sh*t happens, circumstances change. Same applies with a December or even ASCO 2020 date.
Shareholders are reasonable but the ones I know are not stupid. They have drawn a line in the sand. ASCO is pivotal. No announcement then BUT a noteworthy update on DC VAX L, which should be the focus at Industry Theatre and not diversions like combo trials, then LP has bought some breathing room and minimised damage to the pps. But the respite is short lived. She needs to announce top line sometime during the summer. December, 2019 is a non-starter and the market will believe that----no, top line won't be announced until sometime in 2020, if at all. Then there will be no need for investor relations because the party line that DI may parrot will be completely irrelevant. And there may not be a sufficient enough investor population to require the continuation of this function.
Happy, IMHO, a great disservice is done to shareholders by not keeping management's feet to the fire by even suggesting a December, 2019 date. Management reads this MB and they may begin to believe that shareholders will resign themselves to anything including continued silence, inordinate delays in announcing top line, etc., etc. If so, taking things to an extreme, why not just continue the trial indefinitely and continue to collect data? Why not a 2020 spring refresh? How about a 2021 spring refresh and then a fall 2021 refresh? Why announce top line at all? Just say that "we are analysing the results and that is a ginormous and multi-year process after which we will address RA approvals". Stay tuned and BTW, we have a Series ZZ convertible offering if you're interested but you must sign an NDA". LOL.
There is a time when enough is enough. Time has run out. Any unwarranted extensions will be met by severe down drafts in the pps. Toxic financings? You ain't seen nothin' yet. JMHO.
If top line is not announced at ASCO as you surmise, then the share price is going to be severely punished. ASCO is pivotal. However, the degree of punishment will depend on what the update is all about as well as giving an indication when top line can be expected. A dog and pony show with emotional appeal, as presented last year, won't be acceptable and, in fact, will only accelerate the descent of the share price.
I believe LP knows this. If she does not want to play catch up on recovery of the battered share price when top line is finally announced, she will make sure that the update is noteworthy in order to prevent a complete collapse. She will at least definitely announce that SAPs have been submitted and the associated dates. She knows that announcement of top line cannot be delayed much after ASCO. If the summer goes by with no announcement, the share price will undoubtedly hit new lows, perhaps even single digits. Even with good results, that is a difficult hole to climb out of. All this is obvious and LP is under immense pressure to come up with something by ASCO to avoid this "doomsday" incineration of the share price. She cannot afford to let this happen. She and the BOD are perceptive enough to understand all this and that an essentially "stay tuned" message at ASCO, where they have again spent 100s of thousands of $$$, won't cut it. LP ain't that stupid. JMHO.
I have stayed around this long because I believe in the science. I can afford to lose what I have invested. So I am seeing this through at least to the announcement of top line. However, I would be lying if I did not have serious concerns. I think the odds favour generally good results and I think that the stock can rise to a dollar or even two in the relatively short term dependent, of course, upon timely results, despite the machinations of sinister forces. But I am prepared to lose my investment if results are less than stellar. I am betting they will be impressive but it is white knuckles flying into ASCO. I am also betting that this ASCO will be different and that Linda/ Bosch will be wearing more than a G-string at Industry Theatre. If not, I won't be staying tuned. It will be time to change channels. JMHO.
Hb:
With all due respect, I have heard it all before no less than from a Senior VP and former Skadden Arps partner in Washington, DC. DI is continuing the party line. Things have to be aligned just right, the timing is not propitious, the tea leaves have to fall in place and the moon positioned perfectly for the full eclipse, yada,yada,yada.
It was expected by many that top line would be announced by end of 2018 or even in early 2019. Here we are almost half a year later and most probably no announcement or even meaningful news at ASCO 2019. This follows a pattern of dragging on and on for whatever excuse. ASCO 2019 is the watershed event. Essentially if nothing new is revealed, the share price collapses. Perhaps the problem is that management fears the results won't be unequivocal and undeniable. They will need to be defended and explained. NWBO will once again be placed on the defensive and will retreat, as usual, into its lair of silence. Thus the delay. NWBO management is now thinking of how they can explain away less than stellar results. It is beginning to look that way.
Flipper is correct. The time to unblind is well nigh. It is disadvantageous to continue collecting events as patients are older and will die from other causes.
I bet that the SAPs have not even been completed and much more submitted to the RAs. Nothing will be said in the updates except stay tuned. That's a pattern you can depend upon and take to the bank. JMHO.
The text you allegedly received from DI follows the exact same pattern of delay, obfuscation and lack of transparency practiced by LG, even though DI allegedly stated that he is all for transparency. As I have repeatedly said, DI will follow the playbook authored by LG. There is/will be no change from that if he wants to stay employed by NWBO. In any sh*t fight with LG who do you think LP is gonna side with? Trust me when I tell you that DI will not win any debates with LG----nada and none. DI is a cushion for LG supposedly allowing LG, now one step removed from the howling hoi poloi retail shareholders, to turn his attention to other more important priorities.
Shareholders seem to expect too much from DI. He is not a heavy hitter Wall Street insider who knows his way around with a myriad of high level contacts and networks. I wish him good luck as his good luck would be mine as well. But realistically, DI has been hired to do IR and communicate the company's line. This, in and of itself, is a difficult balancing act given NWBO's propensity for lack of transparency and shareholders' frustrations. To many investors who I know, ASCO is a line drawn in the sand. It could spell heavy disappointment and I have to believe DI and management are acutely aware of this. Accordingly, I hope that we are in for a "pleasant" surprise.
ASCO looms as an extremely important pivotal event. Lack of an announcement of top line before or at ASCO will cause the share price to crater and quite dramatically. UNLESS, a meaningful update focused upon DC VAX L and not D, etc.(which would be interpreted as a diversionary tactic by the market) is addressed. At the very least, updates on whether the SAPs have been submitted to the 4 RAs and if so when, number of patients currently alive, guidelines on when top line could be announced(e.g., "any day now", soon, definitely not later than SNO, sometime during 2019....), etc. Providing a meaningful update and not a regurgitated dog and pony show may serve to soften the decline in share price. However, if the delay in announcement is extended throughout the summer, then the share price is certain to hit new lows even unto single digits. Even exceptionally good news energy will be largely spent recovering to share price levels existing prior to a disappointing ASCO. I don't think that even with such news, the share price will rocket by a multiple of 10x. Much more likely by 5x~6x. If the results are mixed/ambiguous, then it is pretty much over. I think we are in for a couple of weeks of white knuckle flying.
There is no question that the share price is heavily manipulated. I think that it will continue to be as malevolent forces apply their stranglehold placing heavy pressure upon any rise in the share price. Current management's lack of credibility will compound this effect. Unless there is a BO/change in management, I don't think that NWBO will reach its full potential for the foreseeable future if ever at all. The current NWBO is in the cross hairs of the powers that be and that is not going to change anytime soon. With any success, these forces will redouble and redouble their efforts to keep the "little engine that could" down and place a lid upon the value of the investment. Unfortunately, there won't be any BO/management change anytime soon as LP & "company" will go it alone. The share price will not hit double digits anytime soon. Dreams of triple digit share prices are Alice-in-Wonderland delusional. Considering my cost level, a couple of bucks ain't bad.
JMHO.
It will rapidly collapse to $0.15 and go to single digits if nothing is announced by September. Between now and ASCO, it is white knuckles as we turbulently approach landing. GLTA.
Puhleeeze GGB:
Look, I hate to be a party pooper, but dreams of $100 billion valuations/$100 per share are highly premature. We are trading at less than $0.34 per share!!!!
We have not even gotten top line yet and don't know when it will be announced. Despite all the promise we have seen including LL remarks, the pps continue to struggle. The powers that be have a strangle hold on NWBO which seems to operate under a dark star. Despite good news, it is constantly beaten back. Top line has to unequivocally be a grand slam home run where results are so clear that they are undeniable even by Stupp, AF, Buzdar, et al. Even if top line is a grand slam and in tandem, NWBO announces that it is filing applications with the requisite RAs, I doubt very much that the pps will sky-rocket 10x current levels. More realistic is a spike to possibly $2.00 and then settling back in the mid-range of $1~$2 until FDA approvals sometime in 2020. Upon approval, I think the stock could double from such mid-range levels, but further appreciation is dependent upon demonstrated commercial performance. The naysayers will liken NWBO to Dendreon so highly likely that the market will take a wait and see position. Of course, if results are less than stellar, NWBO will be a brown dwarf.
If enthusiastic shareholders predict, say $10, this is certainly possible albeit highly unlikely in my view. But $100? That is a fantasy just like winning the lottery. It's a quadrillion to one chance.
I think the dark powers have a strangle hold on NWBO. LP/LG have no market place credibility. I have little doubt that they will continue their pattern of lack of transparency. i doubt very much in any near/intermediate BO and the offers, if any, will be low-ball. LP may get an offer of $3.00 per share, tops, which she will definitely turn down. The odds are that she will have to go it alone. IMHO, it will take years if not a decade to realise full value and with the dark forces that be, realisation of such a value may likely never materialise.
Dreams of lawsuits and the prognostications of SOS will never stop these clandestine forces. For every lawyer that NWBO can muster, these forces will have thousands. They have labyrinthian networks and tentacles everywhere. I doubt very much that the SEC or US Attorney's Office will take on this challenge. It would take years if not decades to resolve and current shareholders will be dead and buried by then. These forces know this only too well. "Everyone" is in on the game. NWBO is the odd man out.
$100? Nah, never happen. I would be delirious with a couple of bucks. I think that is a realistic expectation. JMHO.
GGB:
Really? How would he know? And "cure"? Please, physicians don't use the word "cure". Cancer free and in remission are about as far as they will go. Is Bigger getting this "information" from his paid analyst Dr. Rago?
Look, GGB, no doubt things look promising. Let's not go overboard and talk about cures. We have not seen top line yet. Until we see the results and analysis, it is obviously premature to say "cure".
And........we don't even know what if anything NWBO will present at Industry Theatre. They have done this in prior years. Build-up to ASCO; expensive booth; great anticipation and then? The air is let out of the tire and we are all left with yet another stay tuned. And they are mostly off the air.
Although I am originally from New York, I am from Missouri, the "show me" state, when it comes to NWBO. As other long suffering investors, I am pleased by the recent rise in the pps in anticipation of ASCO announcement/ noteworthy update on DC VAX L. But I hope that this is not like the recent 737 air disasters going into a dive after take-off. It all depends upon what transpires at ASCO. One thing you can be sure of------Dr. Bosch will not be claiming any "cures". Would be nice but it ain't gonna happen. JMHO.
I agree with results first, stock rise second, warrants third but a buy out by year end will just never happen. Further, a buy out anytime soon is not in the cards. Big P may offer one or perhaps even two dollars, not more. But I doubt it. Anyway, LP will never, ever sell for that price. She will go it alone. Forget about a buy out. With good news announcement including a statement to the effect that they will be filing for approvals with the requisite RAs, I think the stock could hit a dollar or more and stay at those levels. With approvals, the stock could easily double. Further appreciation is a wait and see proposition on commercializations results. I think these are realistic expectations. JMHO
How can I join Marzan's minions?
Senti:
So are a lot of investors very hopeful that the SAP(s) have already been submitted and that NWBO has been in contacts/ discussions with the FDA and other RAs in order to expeditiously smooth informal approvals.
If we don't get top line at ASCO, it isn't the end of the world. If LP/MB provide a meaningful presentation update focusing upon DCVAX L, that they have submitted SAPs to the RAs, say about a month ago, and are now momentarily awaiting the go ahead so they can data-lock and shortly thereafter announce top line, I think that will be enough to hold the share price steady for a bit. However, if silence/ no news is protracted, the share price may be severely punished during an indefinite interregnum. A significant portion of the rise in share price post impressive top line may be spent recovering from new lows to just about current levels(e.g., 10 cents to 30 cents). However, if top line is mixed/ mediocre, as interpreted by the market, look out below, it's all she wrote.
That is the reason for Les's statement that they will continue until the results are undeniable, that is, so clear and convincing, that the medical community, shareholders, market and indeed the general public can all understand. Accordingly, how top line impressive results are presented will be of critical importance. JMHO.
Neither. It's "peddle" as in peddling excuses for the "ginormous" delays.
The foot dragging would be on NWBO's part if they have not yet submitted the SAPs to the RAs by now. Management has certainly had enough time to complete and submit. JMHO.
ASCO 2019 is a pivotal event. Investors such as yourself have expectations that NWBO will announce top line at ASCO. If they don't, they need to provide news worthy information on DC VAX L. SAP status and when submitted. Number still alive. Etc. If they don't do at least this, yes, I agree, the stock goes to new lows and quickly. A regurgitated dog and pony show is deadly to the share price. So is very little new information. In that case, the stock will probably experience an accelerated decline which can be reversed by announcement of top line a short while later. Although the stock may be pounded, it may still not have reached new lows. Protracted lack of news/announcement, say into the fall, then the share price will probably tank to the high single digits. Then, even with good news, the stock will spend a lot of its rising energy to regain current price levels.
If news worthy news is announced at ASCO, without top line, there will be disappointment and if no real guidance wrt to when top line may be announced, the stock will depreciate as well but perhaps not as much as in the former scenario. It is folly for NWBO management to believe that a comprehensive update on DC VAX L without top line announcement, will allow a holding action and permit delay until, say, SNO for top line announcement without severe damage to the share price during the interim. I have to believe that management has been talking to the RAs wrt the SAPs and has been working on these SAPs for a long time. In that case, it should be a fairly expeditious sign off by the RAs with data lock to follow. Accordingly, there should be enough time between now and ASCO for a top line announcement.
In any event, lack of top line announcement at ASCO will severely hurt the share price. In this, I agree with you. Let's hope Marzan is right with his prediction. GLTA.
It was Jerry
Marzan:
How do I join your minions club?
Sukus:
It really depends upon what is revealed at ASCO. If, for example, LP provides a very comprehensive update on the blinded data, it is possible, perhaps even probable, that top line could rather be revealed later in the year, say, at SNO. When the JTM article was published just before ASCO 2018 and reviewed there, it was expected that top line would be announced in late 2018 or latest in early 2019. Of course it did not happen. Just like last year, LP/MB could provide just enough of an update on L, and perhaps D, at ASCO with the idea that this should satisfy shareholders and hold them off until the latter part of 2019.
I agree with Flip. They could release top-line relatively soon if they wanted to. For some reason, it appears that someone wants this to drag on and on.
OTOH, a "good" sign may be announcing little, if anything, news worthy at ASCO. Could be that announcing anything then is anti-climatic. The big news--top-line--could be announced right around the corner. Surprise everyone, especially the shorts! With NWBO you just never know.
Stay tuned.
Is the stellar object in M-NWBO a white dwarf, neutron or completely collapsed OR is it on the way to supernova and "death star" to the shorts? Will be a bit more in telescopic focus as it approaches the ASCO event horizon. Stay tuned.
Closer is relative. Still about 25K light years away. M-NWBO is a lot closer.
yes, got my number mixed.
Closer only counts in dancing and horseshoes.
Sukus:
Do you really believe they will announce number of living survivors? Or if and when the SAPs were submitted?
My own belief is that the market expects no news until ASCO. Between now and then, the pps should trend down. If no announcement or noteworthy DC VAX L news at Industry Theatre, the pps will take an unpleasant hit and continue its downward spiral. Now, when I think of the NWBO share price I have nightmares about M 81. I just hate spiralling accretion disks. JMHO
Good plan. It may, unfortunately, likely happen continuing the NWBO pattern. Wait for single digits though and you will be able to buy a ton! :)
Joey:
I admire your optimism and enthusiasm. However, I believe what LP has said. The whole process to data-lock and top line announcement is a ginormous multi-month task. Obtaining the approvals from 4 independent RAs is also something that is not right around the corner. I think that NWBO has not yet completed the SAPs or submitted them to the requisite RAs. Accordingly, the odds are that there will be no top line announcement at ASCO. In any event, ASCO is a pivotal event. NWBO has reserved Industry Theatre. Placeholder or no, they need to provide something new of significance wrt DCVAX L. They need to clearly state that the SAPs have been submitted and when, etc., etc. The update on DCVAX L, if top line is not announced, needs to be more than a regurgitated dog and pony show.
I believe many investors, like yourself and Marzan for example, are expecting top line at ASCO. There will be frustration and great disappointment if it isn't announced. The share price could be devastated if NWBO gives non-meaningful generalities and essentially says "stay tuned" and attempts to divert attention to other subjects like "D" trials as it has in the past with up to now no commencement. And if top line is not announced at ASCO and there is no specific guideline beyond ginormous/multi-month, I think the share price could, well..........look out below. I hope you are right, I really do, but......JMHO.
Sukus:
In this, you are wise beyond your words.
However, if you agreed more with my posts, you would be even wiser still. LOL.
GLTY
In NWBO's case, great top line results do not necessarily translate into a turn-around. NWBO is a targeted company. It is obvious for lack of a better simile that NWBO operates under a dark star. Management has little to no credibility. The market is clearly from Missouri, the "show me" state, when it comes to NWBO. Can it get approval relatively expeditiously or will there be some mysterious regulatory hold-up? If they ultimately obtain approval can they execute commercially? Will they be profitable? Or will they f**k up a wet dream? IMHO, the market is not going to give them any benefit of the doubt. Thus, NWBO will continue to be quite vulnerable for some time. Assuming that it can demonstrate commercial/manufacturing success, then yes, NWBO is a turn-around. However, a R/S prior to this during the vulnerable period is a mistake and a sure invitation for vicious and unrelenting shorting. For now and the foreseeable future, an R/S is just a bad idea and not worth even the time to entertain. But if NWBO can demonstrate a turn around, the share price will take care of itself naturally without need for any R/S gimmicks. JMHO.
Yes, I understand the math. However, NWBO tried the R/S route once before and what happened? Shorted all the way down to a low of $0.14. The next time is gonna be any different? There is always a problem and malevolent event hounding NWBO. If it isn't a regulatory hold up, it's those nasty naked shorts. Those who don't remember history are doomed to repeat it. In NWBO's case, a R/S gives the shorts an engraved invitation to short with impunity at a higher altitude.
In NWBO's case, the market is from Missouri. R/S gimmicks won't work. The market wants NWBO to demonstrate organic and sustainable growth. Great trial results are only the first step. They don't guarantee success. No doubt, the share price will appreciate with good news, but to be sustainable and grow, NWBO will need to demonstrate commercial success. This is not around the corner. NWBO will remain vulnerable for the foreseeable future. Once commercial success is validated, the share price will take care of itself. There will be no need for a R/S "gimmick" because NWBO will be able to achieve the qualifying level for uplifting to a major exchange. In my view, even talking about a R/S now is utter nonsense.
I think NWBO still has a long way to go. Forget about a R/S anytime soon. JMHO.
We will soon find out, won't we? I am betting that this time LP will produce a different show.
Sorry but I completely disagree with you at least insofar as NWBO goes. I think that if results are as good as believed and are undeniably impressive, NWBO share price should rise relatively quickly to a level where they would qualify for uplifting. Given this, I don't believe that NWBO would need to rely on "gimmicks" in order to raise the share price for exchange qualification. They can get to that level on their own steam assuming the results are highly positive. Less than that, a R/S invites heavy shorting in NWBO's case. Nope, a R/S is a bad idea and certainly at this stage. I don't believe that NWBO management is that stupid.
Doc:
Hope you are right. Perhaps ultimately so. But the bigger the fish caught in the net, the longer it takes to filet it. And that is the point. It is time to conclusion and fundamental change in the paradigm. It won't happen overnight. It will be hard fought. And it will not be soon enough to benefit NWBO. The gears of justice, if you will, grind exceedingly slowly. So I do not hold out much hope upon the legal aspects insofar as they may apply to NWBO.
What does matter is the results. If undeniably impressive, as well as reasonably timely announced, we all, patients, shareholders and the public at large, benefit. Malevolent forces will still continue to attempt to thwart the consequences of these results in the market place, but their efforts will be overshadowed by patient and physician demand. However, they will only move on when they realise that they no longer have any significant influence. IMHO, in the foreseeable future, it won't be due to a sea change in the market/legal-regulatory enforcement system.
Insofar as DC VAX i"D" is concerned, I hope so. But first things first. Let's see what happens with "L". Right now that is the ball game, not D. JMHO. Peace.
LP very likely will not announce top line at ASCO. That is not at all a worst scenario unless the Industry Theatre is a "no hamburger" regurgitation of what we already know and stay tuned follow-on message.
IMHO, that won't happen. I would bet, almost certainly, that some noteworthy "new" news concerning DC VAX L will be revealed in a comprehensive update. Then there will be support for the share price and it may sustainably rise for a while. However, if top line announcement is unduly delayed, to, say, the end of 2019, then almost certainly the pps will hit new lows.
Notwithstanding ginormous tasks, multi month processes and RA SAP approvals, I have to believe that NWBO's pedal to the metal seeks to avoid such a devastating scenario. While I am no fan of management, I believe that results will be impressive. Nothing else matters. ASCO is a pivotal event and LP knows it. I think LP would be absolutely crazy to go to Industry Theatre with just a dog and pony show. I also believe that a R/S upon the heels of such a presentation would signal a death knell. I am reasonably certain it won't happen.
Further, NWBO still has a 17 acre parcel that can be used, if necessary, to fund operations before any toxic financing occurs. I think avoiding this is also why NWBO's pedal is on the metal. At this stage, almost certainly, a R/S is off the table. JMHO.